Of the ~400 genes downstream of PERK20 (Supplementary Data 1), only 23 showed at least a twofold increase in expression in cancers relative to normal tissues (Fig. 1a, b; CSPS, cancer-specific PERK set). This evidence concerns the gene EIF2AK3 and cancer.